Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/24/2025

Hidradenitis Suppurativa Management

Initial Assessment and General Recommendations

  • The British Association of Dermatologists recommends recording the Hurley stage for the worst-affected anatomical region, measuring pain using Visual Analog Scale (VAS), and assessing quality of life using Dermatology Life Quality Index (DLQI) for all patients with hidradenitis suppurativa 1, 2
  • The National Institute for Health and Care Excellence suggests screening for comorbidities, such as depression, anxiety, diabetes, hypertension, hyperlipidemia, central obesity, and inflammatory bowel disease, in patients with hidradenitis suppurativa 1, 3
  • The American Academy of Dermatology recommends referring patients with hidradenitis suppurativa to smoking cessation services, as smoking has an odds ratio of 36 for the disease 1, 3
  • The European Academy of Dermatology and Venereology suggests referring patients with hidradenitis suppurativa to weight management services, as obesity has an odds ratio of 33 for the disease 1, 3

Hurley Stage I (Mild Disease) Treatment

  • The British Association of Dermatologists recommends topical clindamycin 1% solution or gel applied twice daily to all affected areas for 12 weeks as first-line treatment for Hurley Stage I disease 2, 3, 4
  • The American Academy of Dermatology suggests combining topical clindamycin with antiseptic washes, such as chlorhexidine 4%, benzoyl peroxide, or zinc pyrithione, to reduce Staphylococcus aureus colonization and antimicrobial resistance risk 2, 4
  • The National Institute for Health and Care Excellence recommends intralesional triamcinolone 10 mg/mL for acutely inflamed nodules, providing rapid symptom relief within 1 day 2, 4

Hurley Stage II (Moderate Disease) Treatment

  • The British Association of Dermatologists recommends clindamycin 300 mg orally twice daily plus rifampicin 300-600 mg orally once or twice daily for 10-12 weeks as first-line treatment for Hurley Stage II disease 1, 2, 3, 4
  • The American Academy of Dermatology suggests continuing topical clindamycin 1% and antiseptic washes as adjunctive therapy for Hurley Stage II disease 2, 4
  • The European Academy of Dermatology and Venereology recommends intralesional triamcinolone 10 mg/mL for individual inflamed lesions during acute flares in Hurley Stage II disease 2, 3

Hurley Stage III (Severe Disease) Treatment

  • The British Association of Dermatologists recommends adalimumab as first-line biologic therapy for Hurley Stage III disease, with a dosing regimen of 160 mg at Week 0, 80 mg at Week 2, and 40 mg weekly starting Week 4 2, 3
  • The American Academy of Dermatology suggests assessing response to adalimumab at 12 weeks using HiSCR and considering alternative treatments if no clinical response by Week 16 2, 4
  • The National Institute for Health and Care Excellence recommends infliximab 5 mg/kg at weeks 0, 2, 6, then every 8 weeks as second-line biologic therapy for Hurley Stage III disease 1, 3, 4

Surgical Interventions

  • The American Academy of Dermatology recommends wide local excision (radical surgical excision) for extensive disease with sinus tracts and scarring in Hurley Stage III disease 1, 2, 3, 5, 4
  • The European Academy of Dermatology and Venereology suggests considering wound closure options, such as secondary intention healing, TDAP flap, delayed primary closure, skin grafts, or substitutes, for surgical interventions in Hurley Stage III disease 1, 2, 5

Adjunctive Therapies

  • The British Association of Dermatologists recommends pain management using NSAIDs for symptomatic relief and considering opioids for severe pain in patients with hidradenitis suppurativa 1, 2, 7
  • The American Academy of Dermatology suggests selecting wound dressings based on drainage amount, anatomical location, and patient preference for patients with hidradenitis suppurativa 1, 2, 5, 7

Long-Term Monitoring

  • The National Institute for Health and Care Excellence recommends monitoring patients with moderate-to-severe hidradenitis suppurativa for fistulating gastrointestinal disease, inflammatory arthritis, genital lymphoedema, cutaneous squamous cell carcinoma, and anemia 1, 3, 7
  • The European Academy of Dermatology and Venereology suggests performing annual TB screening if patients are on glucocorticoids >15 mg prednisone equivalent daily for ≥4 weeks 6